Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2024 08:03 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics initierar en fas 2-studie med sevuparin för behandling av kronisk njursjukdom med anemi

STOCKHOLM, SVERIGE, 9 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har doserat den första patienten i en klinisk fas 2-studie...
December 09, 2024 08:03 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia

STOCKHOLM, SWEDEN – December 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in a phase 2...
December 02, 2024 10:41 ET | Source: Karolinska Development AB (publ)

Karolinska Development genomför organisationsförändringar för en effektivare portföljförvaltning

STOCKHOLM, 2 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att bolaget har beslutat att genomföra organisationsförändringar i syfte att reducera kostnadsbasen för sin...
December 02, 2024 10:41 ET | Source: Karolinska Development AB (publ)

Karolinska Development implements organizational changes for more efficient portfolio management

STOCKHOLM, SWEDEN – December 2, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company has decided to implement organizational changes in order to reduce the cost...
November 19, 2024 11:19 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics säkrar bryggfinansiering

STOCKHOLM, SVERIGE 19 november 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har säkrat bryggfinansiering på upp till 5 miljoner kronor...
November 19, 2024 11:19 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics secures bridge financing

STOCKHOLM, SWEDEN November 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has secured access to bridge financing of up to...
November 18, 2024 03:25 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition presenterar positiva interimdata från klinisk fas 1b/2a-studie

STOCKHOLM, SVERIGE, 18 november 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition kommer att presentera data från en nyligen genomförd...
November 18, 2024 03:25 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study

STOCKHOLM, SWEDEN – November 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present data from a recent interim analysis...
November 15, 2024 02:30 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag SVF Vaccines utser Gaston Picchio som tillförordnad vd

STOCKHOLM, SVERIGE, 15 november 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar i dag att portföljbolaget SVF Vaccines har utsett Gaston Picchio som tillförordnad vd. Han tillträder...
November 15, 2024 02:30 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company SVF Vaccines appoints Dr Gaston Picchio as acting CEO

STOCKHOLM, Sweden, 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will...